| Name: | Dutasteride EP Impurity C |
| Catalogue No. | VL225006 |
| CAS No. | 157307-36-3 |
| Molecular Formula | C21H31NO3 |
| Molecular Weight | 345.48 |
| Status | In-stock |
| IUPAC Name | (4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-Tetradecahydro-4a,6a-dimethyl-2-oxo-1H-Indeno[5,4-f]quinoline-7-carboxylic Acid Ethyl Ester; |
| Description | Dutasteride EP Impurity C (CAS No.157307-36-3) or (4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-Tetradecahydro-4a,6a-dimethyl-2-oxo-1H-Indeno[5,4-f]quinoline-7-carboxylic Acid Ethyl Ester. It is an oral synthetic 4-azasteroid and it is a potent selective inhibitor of type-1 and type-2 5-alpha reductase. It is used in the treatment of moderate to severe symptomatic BPH in men with an enlarged prostate. |
| References | "Nickel, J. Curtis. “Comparison of Clinical Trials with Finasteride and Dutasteride.” Reviews in Urology, vol. 6 Suppl 9, no. Suppl 9, MedReviews, LLC, 2004, pp. S31-9, www.ncbi.nlm.nih.gov/pmc/articles/PMC1472914/. Keam, Susan J., and Lesley J. Scott. “Dutasteride.” Drugs, vol. 68, no. 4, 2008, pp. 463–85, https://doi.org/10.2165/00003495-200868040-00008." |
